title: Systems-level thinking for nanoparticle-mediated therapeutic delivery to neurological diseases.
abstract: Neurological diseases account for 13% of the global burden of disease. As a result, treating these diseases costs $750 billion a year. Nanotechnology, which consists of small (~1-100 nm) but highly tailorable platforms, can provide significant opportunities for improving therapeutic delivery to the brain. Nanoparticles can increase drug solubility, overcome the blood-brain and brain penetration barriers, and provide timed release of a drug at a site of interest. Many researchers have successfully used nanotechnology to overcome individual barriers to therapeutic delivery to the brain, yet no platform has translated into a standard of care for any neurological disease. The challenge in translating nanotechnology platforms into clinical use for patients with neurological disease necessitates a new approach to: (1) collect information from the fields associated with understanding and treating brain diseases and (2) apply that information using scalable technologies in a clinically-relevant way. This approach requires systems-level thinking to integrate an understanding of biological barriers to therapeutic intervention in the brain with the engineering of nanoparticle material properties to overcome those barriers. To demonstrate how a systems perspective can tackle the challenge of treating neurological diseases using nanotechnology, this review will first present physiological barriers to drug delivery in the brain and common neurological disease hallmarks that influence these barriers. We will then analyze the design of nanotechnology platforms in preclinical in vivo efficacy studies for treatment of neurological disease, and map concepts for the interaction of nanoparticle physicochemical properties and pathophysiological hallmarks in the brain. WIREs Nanomed Nanobiotechnol 2017, 9:e1422. doi: 10.1002/wnan.1422 For further resources related to this article, please visit the WIREs website.
authors: Department of Chemical Engineering, University of Washington, Seattle, WA, USA.
authors: Chad
authors: C
authors: Curtis
authors: Molecular Engineering and Sciences Institute, University of Washington, Seattle, WA, USA.
authors: Mengying
authors: M
authors: Zhang
authors: Department of Chemical Engineering, University of Washington, Seattle, WA, USA.
authors: Rick
authors: R
authors: Liao
authors: Department of Physiology, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway.
authors: Thomas
authors: T
authors: Wood
authors: Department of Chemical Engineering, University of Washington, Seattle, WA, USA.|Molecular Engineering and Sciences Institute, University of Washington, Seattle, WA, USA.|Department of Radiology, University of Washington, Seattle, WA, USA.|Center on Human Development and Disability, University of Washington, Seattle, WA, USA.
authors: Elizabeth
authors: E
authors: Nance
mesh_terms: D000818:Animals; D001812:Blood-Brain Barrier; D001927:Brain Diseases / Q000188:drug therapy*; D004195:Disease Models, Animal; D016503:Drug Delivery Systems; D006801:Humans; D051379:Mice; D050997:Nanomedicine / Q000379:methods*; D053758:Nanoparticles / Q000737:chemistry / Q000627:therapeutic use